<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F0C959ED-FFC2-4E63-BA03-CD19885F0FD9"><gtr:id>F0C959ED-FFC2-4E63-BA03-CD19885F0FD9</gtr:id><gtr:firstName>Alexandra</gtr:firstName><gtr:surname>Bazeos</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000262"><gtr:id>1A9D01AE-99AB-43C2-A209-BC61CF99E522</gtr:id><gtr:title>Genome-wide DNA methylation/expression profiling in chronic myeloid leukaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000262</gtr:grantReference><gtr:abstractText>Chronic Myeloid leukaemia (CML) is a cancer of the blood that originates in the bone marrow. The disease comes about when two chromosomes in a developing blood cell (a blood stem cell) swap sections with each other to produce the Philadelphia chromosome. The Philadelphia chromosome creates a new gene, the BCR-ABL1 gene which contains instructions to allow the abnormal blood cell to grow out of control. 
CML has 3 sequential phases designated chronic, accelerated and blastic. The first two phases respond well to use of drugs that block the activity of the BCR-ABL1 protein. Progression to blastic phase invariably ends in death. It is not clear how or why the leukaemia progresses rapidly in some patients but slowly or not at all in others. Though the leukaemia unquestionably originates in primitive blood-forming stem cells it seems that later in the disease more mature blood cells that don?t usually reproduce themselves develop gene alterations that cause them to self-renew and create the clinical features of an aggressive acute leukaemia-like disease. This study will look at how genes are switched on or off via a sequence of DNA-related chemical reactions that control the degree to which they make their respective proteins. We will look at leukaemia cells from patients with CML in the chronic and accelerated phases and compare these to the same cells of healthy subjects to identify which of the many different genes in a person?s body play a key role in causing the leukaemia to progress. New techniques involving both laboratory experiments and computerised mathematical analysis, not available until very recently, will be used to answer these questions.</gtr:abstractText><gtr:technicalSummary>Background
It is generally accepted that cancers are initiated by a distinct population of cancer stem cells (or leukaemia stem cells, LSCs). CML is a clonal haematological malignancy believed to start when a single haematopoietic stem cell (HSC) acquires a BCR-ABL1 fusion gene on the Philadelphia (Ph) chromosome. Understanding the molecular and cellular mechanisms involved in disease progression from chronic phase (CP) to advanced phase (AP) is currently a key issue in the biology of CML. Accumulating data raise the strong possibility that committed progenitors (such as granulocyte-macrophage progenitors, GMP) are in fact responsible for disease progression through the acquisition of self-renewal properties. Aberrant DNA methylation of promoter CpG islands is known to contribute to the overall malignant phenotype in a variety of human cancers including CML. The finding of differences in methylation/transcription patterns between HSCs and GMPs would support the notion that disease progression is due to events occurring in differentiated progeny of the LSC. The availability of techniques to study genome-wide methylation/expression will allow us to identify areas of aberrant methylation and the functional consequences in the various CML sub-populations.
Aims
To investigate the DNA methylation/transcription changes associated with leukaemia stem cells in CML using high-throughput functional genomics. 
Objectives
1. To identify and validate the DNA methylation/transcription differences between CP CML HSCs and their normal counterparts.
2. To compare the DNA methylome/transcriptome of HSCs with that of GMPs in CML in advanced phase on the assumption that acquired changes in the latter may be primarily responsible for disease progression.
3. To perform relevant functional analyses of the identified methylation/transcription perturbations.
Design and methodology
Blood and bone marrow samples will be collected from healthy donors and newly diagnosed patients with CP and AP CML. Homogeneous populations of HSCs and GMPs will be sorted. Methylated DNA immunoprecipitation combined with next generation sequencing (MeDIP-seq), and mRNA-seq will be used to generate whole methylome and transcriptome profiles. Datasets will be integrated and analyzed with a view to identifying differentially methylated regions (DMRs) and transcripts that differentiate (i) chronic phase CML HSCs and their normal counterparts; and (ii) normal GMPs, CML CP GMPs and CML AP GMPs on the assumption that acquired changes in the last group may be primarily responsible for disease progression.
Scientific and Medical opportunities
The application of cutting-edge experimental techniques will allow us to identify mechanisms of leukaemogenesis in CML from a truly genome-wide perspective. In turn, this may improve the diagnosis and use of existing therapies as well as highlight potential new strategies for effectively targeting the LSC.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>207323</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Molecular Biology and Genetics</gtr:department><gtr:description>hydroxymethylation using next gen sequencing</gtr:description><gtr:id>2B58E885-2C69-4A98-A682-EF8E475B0C65</gtr:id><gtr:impact>Currently paper writing</gtr:impact><gtr:outcomeId>SF3XfjwH84P-1</gtr:outcomeId><gtr:partnerContribution>Sequencing including prep and some of the bioinformatic analysis</gtr:partnerContribution><gtr:piContribution>Collection of human cells from the clinic, preparation and selection of relevant cells, DNA preparation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Human Genetics</gtr:department><gtr:description>DNA methylation in cancer</gtr:description><gtr:id>0D921337-17BC-45CD-B012-39F4B2B19AD0</gtr:id><gtr:impact>PI of group has visited our institution to present other relevant data</gtr:impact><gtr:outcomeId>hyRo6AcSesJ-1</gtr:outcomeId><gtr:partnerContribution>Bioinformatic analysis of array data</gtr:partnerContribution><gtr:piContribution>All the laboratory based work including provision of clinical samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>EHA 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>763DBA0A-7D1E-4154-A428-32044B4F7ED6</gtr:id><gtr:impact>Request for collaboration. One group seem to be replicating the work now in Australia!

Interest of role of DNA methylation in Leukaemia is increasing</gtr:impact><gtr:outcomeId>dXXMSM1sTEL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to european haematologists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2517B246-15CB-4689-BABB-84900B0E40F6</gtr:id><gtr:impact>The scientific presentation I give in DNA Methylation in CML provokes interest and there are always a few health care professionals who maintain contact and even send samples for me to use

The preceptorship programme for european haematologists has become such a popular occasion that the meeting has now run 3 times</gtr:impact><gtr:outcomeId>Xe9ZdzPH42p</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advisory group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6C3FBA39-AFF1-4BB5-8E06-A494FA65E41C</gtr:id><gtr:impact>Ongoing process organised by Anthony Nolan Trust

Ongoing</gtr:impact><gtr:outcomeId>mj4jYLJZS2W</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>27000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Leuka</gtr:fundingOrg><gtr:id>BCFCB9EE-1178-407E-B3D1-35FEE469AB42</gtr:id><gtr:outcomeId>SwHohCQV4y3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G1000262</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>